全文获取类型
收费全文 | 2444篇 |
免费 | 122篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 74篇 |
妇产科学 | 20篇 |
基础医学 | 308篇 |
口腔科学 | 74篇 |
临床医学 | 160篇 |
内科学 | 796篇 |
皮肤病学 | 24篇 |
神经病学 | 100篇 |
特种医学 | 46篇 |
外科学 | 447篇 |
综合类 | 6篇 |
预防医学 | 92篇 |
眼科学 | 83篇 |
药学 | 116篇 |
中国医学 | 5篇 |
肿瘤学 | 220篇 |
出版年
2023年 | 18篇 |
2022年 | 35篇 |
2021年 | 70篇 |
2020年 | 20篇 |
2019年 | 51篇 |
2018年 | 47篇 |
2017年 | 58篇 |
2016年 | 44篇 |
2015年 | 57篇 |
2014年 | 94篇 |
2013年 | 77篇 |
2012年 | 141篇 |
2011年 | 158篇 |
2010年 | 78篇 |
2009年 | 76篇 |
2008年 | 115篇 |
2007年 | 115篇 |
2006年 | 108篇 |
2005年 | 128篇 |
2004年 | 113篇 |
2003年 | 126篇 |
2002年 | 81篇 |
2001年 | 67篇 |
2000年 | 68篇 |
1999年 | 73篇 |
1998年 | 24篇 |
1997年 | 9篇 |
1996年 | 11篇 |
1995年 | 12篇 |
1994年 | 17篇 |
1993年 | 10篇 |
1992年 | 52篇 |
1991年 | 53篇 |
1990年 | 37篇 |
1989年 | 45篇 |
1988年 | 37篇 |
1987年 | 31篇 |
1986年 | 26篇 |
1985年 | 16篇 |
1984年 | 13篇 |
1983年 | 15篇 |
1979年 | 20篇 |
1978年 | 16篇 |
1977年 | 17篇 |
1976年 | 9篇 |
1975年 | 10篇 |
1973年 | 11篇 |
1972年 | 10篇 |
1970年 | 8篇 |
1969年 | 8篇 |
排序方式: 共有2580条查询结果,搜索用时 15 毫秒
61.
A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma 总被引:35,自引:0,他引:35
Shiina S Teratani T Obi S Sato S Tateishi R Fujishima T Ishikawa T Koike Y Yoshida H Kawabe T Omata M 《Gastroenterology》2005,129(1):122-130
BACKGROUND & AIMS: Percutaneous radiofrequency ablation is a recently introduced treatment for hepatocellular carcinoma, whereas ethanol injection is now a standard therapy. We compared their long-term outcomes. METHODS: Two hundred thirty-two patients with hepatocellular carcinoma who had 3 or fewer lesions, each 3 cm or less in diameter, and liver function of Child-Pugh class A or B were entered onto a randomized controlled trial. The primary end point was survival, and the secondary end points were overall recurrence and local tumor progression. RESULTS: One hundred eighteen patients were assigned to radiofrequency ablation and 114 to ethanol injection. The number of treatment sessions was smaller (2.1 times vs 6.4 times, respectively, P < .0001) and the length of hospitalization was shorter (10.8 days vs 26.1 days, respectively, P < .0001) in radiofrequency ablation than in ethanol injection. Four-year survival rate was 74% (95% CI: 65%-84%) in radiofrequency ablation and 57% (95% CI: 45%-71%) in ethanol injection. Radiofrequency ablation had a 46% smaller risk of death (adjusted relative risk, 0.54 [95% CI: 0.33-0.89], P = .02), a 43% smaller risk of overall recurrence (adjusted relative risk 0.57 [95% CI: 0.41-0.80], P = .0009), and an 88% smaller risk of local tumor progression (relative risk, 0.12 [95% CI: 0.03-0.55], P = .006) than ethanol injection. The incidence of adverse events was not different between the 2 therapies. CONCLUSIONS: Judging from higher survival but similar adverse events, radiofrequency ablation is superior to ethanol injection for small hepatocellular carcinoma. 相似文献
62.
Masahiko Nakayama Hisanori Kobayashi Koji Fukushima Miwako Ishido Yuji Komada Kazutake Yoshizawa 《Hepatology International》2016,10(1):158-168
Background
Simeprevir with peginterferon and ribavirin has been used for the treatment of chronic hepatitis caused by genotype 1 hepatitis C virus (HCV). We explored the predictive factors for sustained virological response (SVR) and viral relapse using datasets from four Japanese phase 3 studies (CONCERTO).Methods
We used a multiple logistic regression model. First, an integrated dataset comprising 357 patients was analyzed. Subsequently, prior treatment-naïve and relapser (223 patients) and nonresponder (134 patients) of interferon-based treatment subsets were analyzed to identify predictors of SVR. A subset of nonresponders (106 patients) who were treated ≥24 weeks was also analyzed to identify predictors for viral relapse.Results
In the integrated dataset, prior treatment response was significantly associated with SVR. In subset analyses, interleukin-28B (IL28B) TT genotype and undetectable plasma HCV RNA level at week 4 were associated in treatment-naïve patients and relapsers [odds ratio (OR); 4.106 and 3.701, respectively]. In the nonresponders, the IL28B TT genotype population was very small, and inosine triphosphatase (ITPA) and undetectable plasma HCV RNA at week 4 were associated (OR; 2.506 and 3.333, respectively). Furthermore, ribavirin dose intensity (RBV-DI) and detectable plasma HCV RNA at week 4 were significantly associated with viral relapse (OR; 0.327 and 2.922, respectively).Conclusion
IL28B and plasma HCV RNA level at week 4 were clinically relevant predictive factors for SVR in treatment-naïve patients and relapsers. Moreover, RBV-DI and plasma HCV level at week 4 were identified as relevant predictive factors for viral relapse in nonresponders.63.
64.
Yasuhiro Miyake Kazuhide Yamamoto Hiroshi Matsushita Masanori Abe Atsushi Takahashi Takeji Umemura Atsushi Tanaka Makoto Nakamuta Yasunari Nakamoto Yoshiyuki Ueno Toshiji Saibara Hajime Takikawa Kaname Yoshizawa Hiromasa Ohira Mikio Zeniya Morikazu Onji Hirohito Tsubouchi Intractable Hepato‐Biliary Disease Study Group of Japan 《Hepatology research》2014,44(13):1299-1307
65.
66.
Nobuaki Sakamoto Huanhuan Hu Akiko Nanri Tetsuya Mizoue Masafumi Eguchi Takeshi Kochi Tohru Nakagawa Toru Honda Shuichiro Yamamoto Takayuki Ogasawara Naoko Sasaki Akiko Nishihara Teppei Imai Toshiaki Miyamoto Makoto Yamamoto Hiroko Okazaki Kentaro Tomita Akihiko Uehara Ai Hori Makiko Shimizu Taizo Murakami Keisuke Kuwahara Ami Fukunaga Isamu Kabe Tomofumi Sone Seitaro Dohi 《Journal of diabetes investigation.》2020,11(3):719-725
67.
68.
69.
Enooku K Tateishi R Kanai F Kondo Y Masuzaki R Goto T Shiina S Yoshida H Omata M Koike K 《Journal of gastroenterology》2012,47(1):71-78
Background
We evaluated the usefulness of tumor marker doubling time (DT) as an efficacy indicator of a molecular targeted anticancer agent. 相似文献70.
Matsumoto A Tanaka E Morita S Yoshizawa K Umemura T Joshita S 《Journal of gastroenterology》2012,47(9):1006-1013